Recombinant <scp>IGFBP</scp>‐3 inhibits allergic lung inflammation, <scp>VEGF</scp> production, and vascular leak in a mouse model of asthma

Abstract

These results indicate that IGFBP-3 administered exogenously may attenuate antigen-induced airway inflammation and hyper-responsiveness through the modulation of vascular leakage and VEGF expression mediated by HIF-1α/HIF-2α signaling as well as IGF-I action in allergic airway disease of mice.